Daratumumab and Hyaluronidase-fihj

DRUG11 trials

Sponsors

ECOG-ACRIN Cancer Research Group, Takeda, Abdullah Khan, Barry A. Boilson, Thomas Jefferson University

Conditions

AL AmyloidosisAmyloid Light-chain AmyloidosisCardiac TransplantMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaNewly Diagnosed Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Non-small Cell Lung Cancer With STK11/LKB1 Mutation

Phase 1

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

TerminatedNCT04776018

TakedaRelapsed and/or Refractory Multiple Myeloma (RRMM)

Start: 2021-04-20End: 2023-11-09Updated: 2024-10-02

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

TerminatedNCT04956302

Abdullah KhanRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2021-09-27End: 2022-06-16Updated: 2024-06-06

Phase 2

Daratumumab in HLA Desensitization Prior to Transplantation

Enrolling by invitationNCT05300451

Barry A. BoilsonCardiac Transplant

Start: 2022-03-31End: 2026-08-31Target: 10Updated: 2025-10-30

Daratumumab in STK11 Mutated NSCLC

CompletedNCT05807048

NYU Langone HealthNon-small Cell Lung Cancer With STK11/LKB1 Mutation

Start: 2023-06-01End: 2025-11-11Updated: 2026-03-10

Daratumumab for Polyneuropathy Associated With MGUS

WithdrawnNCT06046287

Georgetown UniversityMonoclonal Gammopathy of Undetermined Significance, Peripheral Neuropathy

Start: 2025-09-26End: 2025-09-26Updated: 2025-10-01

Teclistamab-Daratumumab in AL Amyloidosis

RecruitingNCT07110844

Suzanne Lentzsch, MDAmyloid Light-chain Amyloidosis

Start: 2025-11-07End: 2033-10-31Target: 25Updated: 2025-11-19

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Not yet recruitingNCT07247097

Massachusetts General HospitalMultiple Myeloma, Newly Diagnosed Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM) +1

Start: 2026-04-15End: 2035-12-01Target: 160Updated: 2025-11-25

Phase 3

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

RecruitingNCT04566328

ECOG-ACRIN Cancer Research GroupPlasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma

Start: 2021-02-24End: 2027-12-31Target: 1450Updated: 2026-04-03

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

RecruitingNCT05561387

SWOG Cancer Research NetworkPlasma Cell Myeloma

Start: 2023-10-12End: 2031-05-30Target: 510Updated: 2025-06-04

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

RecruitingNCT06022939

SWOG Cancer Research NetworkAL Amyloidosis

Start: 2024-07-01End: 2030-10-29Target: 338Updated: 2025-09-15

Phase 4

Home Based Daratumumab Administration for Patients With Multiple Myeloma

CompletedNCT05511428

Thomas Jefferson UniversityPlasma Cell Myeloma

Start: 2022-11-08End: 2024-05-22Updated: 2025-11-21

Related Papers

Open-label, single-arm study to assess the implementation of and patient experience with home-based daratumumab administration in patients being treated for multiple myeloma

BMJ Connections Oncology2025-09-01

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Blood2024-11-05

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Blood2024-11-05

A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.

Journal of Clinical Oncology2024-06-01

Open label single arm study to assess the implementation of home based daratumumab administration in patients being treated for multiple myeloma.

Journal of Clinical Oncology2023-06-011 citations

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

Blood2022-02-2866 citations

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Blood2021-11-052 citations

A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.

2021-09-15105 citations

ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation.

Journal of Clinical Oncology2021-05-203 citations